Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SCN4A | P35499 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.50 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.50 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.50 |
| ▸ | HEXA | P06865 | 4/20 | 0.44 |
| ▸ | HEXB | P07686 | 4/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 4/20 | 0.43 |
| ▸ | DHFR | P00374 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29384947 | 1.00 | CYP2D6 (0.50) | CYP2D6ADRA1AMAOAMAPK1SCN4A | |
| Hydrochloric Acid SCHEMBL7767228 | 0.99 | CYP2D6 (0.49) | CYP2D6ADRA1AMAOAMAPK1SCN4A | |
| SCHEMBL324896 | 0.90 | CYP2D6 (0.42) | CYP2D6ADRA1AMAOAMAPK1SCN4A | |
| SCHEMBL5566857 | 0.89 | CYP2D6 (0.48) | CYP2D6ADRA1AMAOAMAPK1SCN4A | |
| SCHEMBL7771204 | 0.86 | CYP2D6 (0.39) | CYP2D6ADRA1AMAOAMAPK1SCN4A | |
| SCHEMBL6049489 | 0.85 | HEXA (0.62) | CYP2D6ADRA1AMAOAMAPK1SCN4A | |
| SCHEMBL6049486 | 0.85 | CYP2D6 (0.50) | CYP2D6ADRA1AMAOAMAPK1SCN4A | |
| SCHEMBL5069251 | 0.82 | HEXA (0.48) | CYP2D6ADRA1AMAOAMAPK1SCN4A | |
| SCHEMBL5072676 | 0.82 | CYP2D6 (0.47) | CYP2D6ADRA1AMAOAMAPK1SCN4A | |
| SCHEMBL136398 | 0.81 | HEXA (0.43) | CYP2D6ADRA1ASCN5ASCN9ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | claimed |
| US-8093268-B2 | Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-) | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | claimed |
| US-20100105688-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | US | claimed |
| EP-2129381-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3, 5-DIAMIN0-6- (2, 3-DICHL0PHENYL) -L, 2, 4-TRIAZINE OR R (-) -2, 4-DIAMINO-5- (2, 3-DICHLOROPHENYL) -6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | Glaxo Group Limited (GB) | 2009-12-09 | — | — | EP | claimed |
| WO-2008090117-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3, 5-DIAMIN0-6- (2, 3-DICHL0PHENYL) -L, 2, 4-TRIAZINE OR R (-) -2, 4-DIAMINO-5- (2, 3-DICHLOROPHENYL) -6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | GLAXO GROUP LIMITED (GB) | 2008-07-31 | — | — | WO | claimed |
| US-6548507-B1 | Use of sodium channel antagonists in the treatment of diseases mediated or exacerbated by neuronal apoptosis, such as multiple sclerosis; administering drugs such as lamotrigine | SMITHKLINE BEECHAM CORPORATION | 2003-04-15 | — | — | US | claimed |
| EP-0715851-B1 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | WELLCOME FOUND (GB) | 2003-04-02 | — | — | EP | claimed |
| US-20030008842-A1 | Formulations of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-09 | — | — | US | claimed |
| EP-0879230-B1 | OPTICALLY ACTIVE PHENYL PYRIMIDINE DERIVATIVE AS ANALGESIC AGENT | GLAXO GROUP LTD (GB) | 2001-07-25 | — | — | EP | claimed |
| US-6124308-A | ANALGESICS, ANTICONVULSANTS, TREATING IRRITABLE BOWEL SYNDROME OR BIPOLAR DISORDER | GLAXO WELLCOME INC. (US) | 2000-09-26 | — | — | US | claimed |
| EP-0879230-A2 | OPTICALLY ACTIVE PHENYL PYRIMIDINE DERIVATIVE AS ANALGESIC AGENT | GLAXO GROUP LIMITED (GB) | 1998-11-25 | — | — | EP | claimed |
| WO-1997009317-A2 | OPTICALLY ACTIVE PHENYL PYRIMIDINE DERIVATIVE AS ANALGESIC AGENT | GLAXO GROUP LIMITED (GB) | 1997-03-13 | — | — | WO | claimed |
| US-5597828-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS CEREBRAL ISCHEMIC DAMAGE AND EPILEPSY | GLAXO WELLCOME INC. (US) | 1997-01-28 | — | — | US | claimed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4484952-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | The Regents of the University of California (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| EP-0715851-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-06-12 | — | — | EP | disclosed |
| EP-0713703-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-05-29 | — | — | EP | disclosed |
| US-5136080-A | Intermediates for glutamate inhibitors | BURROUGHS WELLCOME CO. (US) | 1992-08-04 | — | — | US | disclosed |
| EP-0372934-A2 | Pharmacologically active CNS compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105688-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | KCNJ2, SCN5A, GRIK5 | CYP2D6 407/4885ADRA1A 637/4885MAOA 1661/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | CYP2D6 4211/4885ADRA1A 4619/4885MAOA 4874/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | CYP2D6 4391/4885ADRA1A 903/4885MAOA 939/4885 |
| US-20030008842-A1 | Formulations of adenosine a1 agonists | ADORA1, ADORA2B, ADORA2A | CYP2D6 948/4885ADRA1A 6/4885MAOA 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.